began treatment with minocycline hydrochloride, a 3-week prednisone taper, and tacrolimus ointment but experienced no improvement.
On presentation to our clinic (6 months after the procedure), she had noticeably hypopigmented facial skin, suggestive of fairly aggressive resurfacing. On the forehead and cheeks, she had ill-defined, erythematous patches with weeping erosions, crusting, and scattered pustules ( Figure 1A) .
Punch biopsy demonstrated nonspecific changes ( Figure 2) . Swab culture of a pustule was negative for bacterial, viral, or fungal organisms, although anaerobic bacteria and mycobacteria could not be investigated. Blood test results were negative for antinuclear, desmoglein 1 and 3, and bullous pemphigoid (anti-BP180 and anti-BP230) antibodies.
After considering various possibilities (Table) , we reached a diagnosis of facial EPD. We initiated treatment with prednisone at 1 mg/kg/d (tapered over 5 months), clobetasol propionate cream, and mupirocin ointment while continuing therapy with minocycline and tacrolimus ointment.
One month later, we initiated treatment with dapsone, 100 mg daily, owing to minimal improvement. After several months, her condition improved tremendously ( Figure 1B ). After 6 months, improvement plateaued, and treatment with isotretinoin, 30 mg daily, was initiated. Ultimately, she received dapsone for 3½ years (maintenance dose, 25-50 mg daily) and isotretinoin for 2½ years (maintenance dose, 10-20 mg daily; cumulative dose, 250 mg/kg) and experienced further improvement ( Figure 1C ). Her lesions flared on a single occasion as a result of secondary Staphylococcus aureus infection (culture proven) but responded without further flares to long-term antibiotic therapy (cephalexin or azithromycin) and vinegar soaks.
Four years after the original procedure, she continued to have persistent, dry, yellow crusting and mild erythema.
Case 2
A woman in her 60s underwent upper-eyelid blepharoplasty and full-face, fully ablative carbon dioxide laser resurfacing for photoaging (eTable in the Supplement). After experiencing near-complete healing, she developed erosions and crusting along the forehead and jawline. Punch biopsy showed dermal fibrosis. Wound culture results were negative for bacterial, mycobacterial, fungal, or viral organisms. Treatment was attempted with oral antifungal, antiviral, and antibacterial agents as well as topical antimicrobial and emollient therapies.
One year after the procedure, she presented to our clinic with bright erythema, small scattered erosions, and yellow crusts on the forehead, cheeks, and chin. A second punch biopsy showed patchy dermal inflammation and fibrosis. Tissue and swab cultures were negative for bacterial, mycobacterial, viral, and fungal organisms, although anaerobic bacteria could not be investigated.
She was diagnosed with EPD, and we initiated treatment with desonide ointment; petrolatum ointment; and valacyclovir hydrochloride, 500 mg daily, as a precaution. Over the next year, the erosions slowly healed to lightly erythematous patches and persistent, focal areas of adherent crust.
Case 3
A woman in her 60s underwent a full-face chemical peel with Jessner solution plus 35% trichloroacetic acid for actinic damage, blepharoplasty, and a face-lift (eTable in the Supplement). She experienced complete healing.
Approximately 10 weeks after her procedures, she developed weepy, eroded, tender erythematous patches with scattered crusting on the cheeks and temples. Wound cultures were negative for bacterial or fungal organisms. Her condition improved slightly after treatment with diluted vinegar soaks, petrolatum ointment, and oral and topical antibacterial agents. Two years after the procedure, she continued to have erosions and yellow crusting.
On presentation to our clinic, she declined a biopsy, and a clinical diagnosis of EPD was rendered. Because she preferred to avoid treatment with oral corticosteroids, dapsone, or isotretinoin, we initiated a 3-month course of minocycline; dapsone gel, 5%; triamcinolone acetonide ointment, 0.025%; tacrolimus ointment, 0.1%; and emollients. Her skin slowly improved with frequent emollient use over the next 4 years.
Discussion
Erosive pustular dermatosis is a rare, idiopathic, and recalcitrant condition that typically affects the scalp.
2 Here,wepresent 3 cases of EPD isolated to the face and occurring after ablative resurfacing procedures. We suspect that similar cases have occurred but remain undiagnosed or unreported, 6 including 2 cases of "delayed healing without a known cause" after full-face ablative laser resurfacing.
7
Weeks to months after initial postoperative healing, our patients developed erosions, crusting, and brightly erythematous patches in previously resurfaced areas, especially the forehead and lateral cheeks. Like classic EPD, lesions arose in actinically damaged areas following trauma (resurfacing) and demonstrated nonspecific histopathological findings and recalcitrance to treatment.
We deemed EPD to be the best diagnosis after considering other possibilities (Table) . Like classic EPD, our cases illustrate that EPD following resurfacing procedures is made clinically as a diagnosis of exclusion. 
Key Points
Question What is the best unifying diagnosis and treatment approach for recalcitrant facial erosions following ablative resurfacing procedures?
Findings In this case series of 3 women presenting with persistent facial erosions after resurfacing procedures for actinic damage, all were diagnosed with facial erosive pustular dermatosis. Treatment was challenging and improvement occurred slowly over months to years.
Meaning Facial erosive pustular dermatosis should be considered in the differential diagnosis of nonhealing erosions following resurfacing procedures; anti-inflammatory therapies and tincture of time are central to improvement.
In classic EPD, histologic examination and cultures are generally negative for microorganisms. Staphylococcus aureus and Candida albicans can occasionally be isola- Consistent with classic EPD, the lesions in our patients were challenging to treat. Based on our experience, if a diagnosis of facial EPD following an ablative procedure is rendered, we suggest initially considering treatment with potent topical corticosteroids, mupirocin ointment, and/or oral tetracyclines. In addition, if prednisone therapy starting at 1 mg/kg/d and tapered over several months is not beneficial, dapsone and/or isotretinoin therapy should be considered. Tincture of time is essential to the healing process. Patients should be continually reassured that the condition can take years to improve and may leave scarring. Additional investigation may reveal whether other anti-inflammatory or wound healing modalities are beneficial, such as photodynamic therapy, biologic agents, or minuscule skin grafting. 8, 9 Our observations have implications regarding the type of injury that incites EPD. Blepharoplasty may have played a contributory role, but resurfacing procedures were likely paramount in eliciting EPD in our patients. Indeed, the shared feature of our patients is that their lesions were localized to skin treated with resurfacing procedures that ablate down to the superficial to mid-dermis. Thus, damage to both the epidermis and upper dermis appears sufficient for promoting the development of EPD. It remains unclear whether fractionated lasers, which cause less injury and inflammation than do fully ablative or other procedures, 10 may similarly elicit EPD.
Alternatively, fractionated lasers may represent an option for improving facial EPD by stimulating wound healing.
11
The 3 cases described here suggest that certain inflammatory elements play a pathogenic role in EPD.
12 During the initial weeks following treatment, fully ablative carbon dioxide laser resurfacing strongly induces proinflammatory cytokines (eg, interleukin 1β, tumor necrosis factor) and matrix metalloproteinases while stimulating neutrophil and macrophage influx into ablated areas. 13 Similar cytokines may be produced after chemical peels. 14 As such, these proinflammatory mediators and cells may play pathogenic roles in eliciting EPD, 15 particularly following ablative procedures. Anti-inflammatory therapies, such as dapsone, likely produce clinical benefit by reducing some of these alterations.
Conclusions
Facial EPD following ablative procedures may develop months after initial postoperative healing, resulting in delayed diagnosis. It is a diagnosis of exclusion and appears to be rare, idiosyncratic, and recalcitrant. Punch biopsy specimen from the forehead showed nonspecific features, including impetiginized scale-crust with underlying dermal fibrosis and acute and chronic inflammation, consistent with reparative changes (hematoxylin-eosin, original magnification ×100). 
